Suppression of IL-23-mediated Psoriasis-like Inflammation by Regulatory B Cells

Overview

Journal Sci Rep

Specialty Science

Date 2021 Jan 23

PMID 33483537

Citations 10

Authors

Kie Mizumaki

Motoki Horii

Miyu Kano

Akito Komuro

Takashi Matsushita

Affiliations

Soon will be listed here.

Abstract

Psoriasis is an inflammatory cutaneous disease mediated by T-cell dependent immune responses; however, B cells are also considered to play an important role its development. Regulatory B cells (Bregs) regulate immune responses negatively through interleukin-10 (IL-10) production. This study aimed to investigate the role of Bregs in IL-23-mediated psoriasis-like inflammation in mice. Psoriasis-like inflammation was induced in B cell-specific phosphatase and tensin homolog (PTEN)-deficient mice, in which Bregs were significantly expanded, and in their controls, by intradermal injection of 20 μL phosphate-buffered saline (PBS) containing 0.5 μg rmIL-23 into one ear, every other day for 16 days. IL-23-mediated psoriasis-like inflammation was suppressed in B cell-specific PTEN-deficient mice along with decreased ear thickness and epidermal thickness on day 15. Moreover, adoptive transfer of B1 B cells suppressed IL-23-mediated psoriasis-like inflammation. rmIL-23-injected B cell-specific PTEN-deficient mice showed expanded regulatory T cells (Tregs) in the spleen and draining lymph nodes along with increased Bregs. Further, T helper (Th) 17 differentiation in the rmIL-23-injected ear was suppressed in B cell-specific PTEN-deficient mice. Overall, these results indicate that increased Bregs suppress IL-23-mediated psoriasis-like inflammation through Treg expansion and inhibition of Th17 differentiation. Thus, targeting Bregs may be a feasible treatment strategy for psoriasis.

Citing Articles

Causal association between B cell count and psoriasis using two-sample Mendelian randomization.

Zhao Z, Cheng J, Zhu J, Lu S, Lv H, Wu X J Cell Mol Med. 2024; 28(17):e70089.

PMID: 39261978 PMC: 11390492. DOI: 10.1111/jcmm.70089.

Yinxie I Formula attenuates imiquimod-induced psoriasis-like skin inflammation via IL-23/IL-17 axis.

Yanping H, Ting G, Xinzhu Z, Yaya L, Yuna Z, Qing L Arch Dermatol Res. 2024; 316(8):540.

PMID: 39158742 PMC: 11333517. DOI: 10.1007/s00403-024-03288-3.

TAZ deficiency exacerbates psoriatic pathogenesis by increasing the histamine-releasing factor.

Song J, Kim H, Cho H, Yoon S, Lim J, Lee K Cell Biosci. 2024; 14(1):60.

PMID: 38734624 PMC: 11088771. DOI: 10.1186/s13578-024-01246-0.

The Immunology of Psoriasis-Current Concepts in Pathogenesis.

Sieminska I, Pieniawska M, Grzywa T Clin Rev Allergy Immunol. 2024; 66(2):164-191.

PMID: 38642273 PMC: 11193704. DOI: 10.1007/s12016-024-08991-7.

Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas.

Pfeuffer S Mult Scler. 2024; 30(7):897-898.

PMID: 38385204 PMC: 11134968. DOI: 10.1177/13524585241232283.

References

Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg R, Bhan A . Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002; 16(2):219-30. DOI: 10.1016/s1074-7613(02)00274-1. View

Lu J, Xu X, Li Y, Yu N, Ding Y, Shi Y . Local reinfusion of B10 cells is effective in the treatment of pustular psoriasis. Dermatol Ther. 2020; 33(4):e13645. DOI: 10.1111/dth.13645. View

Mauri C . Regulation of immunity and autoimmunity by B cells. Curr Opin Immunol. 2010; 22(6):761-7. DOI: 10.1016/j.coi.2010.10.009. View

Alrefai H, Muhammad K, Rudolf R, Pham D, Klein-Hessling S, Patra A . NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. Nat Commun. 2016; 7:11724. PMC: 4894959. DOI: 10.1038/ncomms11724. View

Hayashi M, Yanaba K, Umezawa Y, Yoshihara Y, Kikuchi S, Ishiuji Y . IL-10-producing regulatory B cells are decreased in patients with psoriasis. J Dermatol Sci. 2015; 81(2):93-100. DOI: 10.1016/j.jdermsci.2015.11.003. View

Mavropoulos A, Zafiriou E, Simopoulou T, Brotis A, Liaskos C, Roussaki-Schulze A . Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis. Rheumatology (Oxford). 2019; 58(12):2240-2250. DOI: 10.1093/rheumatology/kez204. View

Mauri C, Gray D, Mushtaq N, Londei M . Prevention of arthritis by interleukin 10-producing B cells. J Exp Med. 2003; 197(4):489-501. PMC: 2193864. DOI: 10.1084/jem.20021293. View

Kopp T, Lenz P, Bello-Fernandez C, Kastelein R, Kupper T, Stingl G . IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol. 2003; 170(11):5438-44. DOI: 10.4049/jimmunol.170.11.5438. View

Lebien T, Tedder T . B lymphocytes: how they develop and function. Blood. 2008; 112(5):1570-80. PMC: 2518873. DOI: 10.1182/blood-2008-02-078071. View

10.

Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein M, Isenberg D . CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013; 5(173):173ra23. DOI: 10.1126/scitranslmed.3005407. View

11.

Nestle F, Kaplan D, Barker J . Psoriasis. N Engl J Med. 2009; 361(5):496-509. DOI: 10.1056/NEJMra0804595. View

12.

Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K . Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol. 2010; 184(9):4801-9. PMC: 3734559. DOI: 10.4049/jimmunol.0902385. View

13.

Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M . Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology (Oxford). 2015; 55(2):263-7. DOI: 10.1093/rheumatology/kev331. View

14.

Mauri C, Menon M . The expanding family of regulatory B cells. Int Immunol. 2015; 27(10):479-86. PMC: 4587489. DOI: 10.1093/intimm/dxv038. View

15.

Fillatreau S . Novel regulatory functions for Toll-like receptor-activated B cells during intracellular bacterial infection. Immunol Rev. 2011; 240(1):52-71. DOI: 10.1111/j.1600-065X.2010.00991.x. View

16.

Blair P, Chavez-Rueda K, Evans J, Shlomchik M, Eddaoudi A, Isenberg D . Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol. 2009; 182(6):3492-3502. PMC: 4082659. DOI: 10.4049/jimmunol.0803052. View

17.

Chan J, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S . IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006; 203(12):2577-87. PMC: 2118145. DOI: 10.1084/jem.20060244. View

18.

Matsushita T, Horikawa M, Iwata Y, Tedder T . Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol. 2010; 185(4):2240-52. PMC: 3717968. DOI: 10.4049/jimmunol.1001307. View

19.

Di Cesare A, Di Meglio P, Nestle F . The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009; 129(6):1339-50. DOI: 10.1038/jid.2009.59. View

20.

Cohen J . Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis. 2008; 67(11):1647-8. DOI: 10.1136/ard.2007.085290. View